Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: tolvaptan Clear all
Completed Phase 1 Interventional

Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study

NCT02096965
View directory record Official record
Conditions
Nephrolithiasis, Calcium Oxalate, Nephrolithiasis, Calcium Phosphate
Interventions
Tolvaptan, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Oct 23, 2026, 1:07 AM EDT
Completed Phase 2 Interventional Results available

Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT00413777
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
11
States / cities
Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 1:07 AM EDT
Withdrawn Not applicable Interventional

Fractional Urate Excretion in Nonedematous Hyponatremia

NCT01425125
View directory record Official record
Conditions
Cerebral Hyponatremia, SIADH, Cerebral Salt-wasting Syndrome, Reset Hypothalamic Osmostat
Interventions
Tolvaptan in euvolemic hyponatremia
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 23, 2026, 1:07 AM EDT
Completed Not applicable Interventional Results available

TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study

NCT02538016
View directory record Official record
Conditions
Cystinuria
Interventions
Tolvaptan
Drug
Lead sponsor
Caleb Nelson
Other
Eligibility
12 Years to 29 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2020 · Synced Oct 23, 2026, 1:07 AM EDT
Recruiting Phase 2 Interventional

Bempedoic Acid Therapy for Polycystic Kidney Disease

NCT07282821
View directory record Official record
Conditions
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Interventions
Bempedoic Acid 180 MG Oral Tablet, Placebo Capsule(s)
Drug
Lead sponsor
Kenneth Hallows
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 1:07 AM EDT
Completed Phase 4 Interventional Results available

Aquaresis Utility for Hyponatremic Acute Heart Failure Study

NCT02183792
View directory record Official record
Conditions
Heart Failure
Interventions
Tolvaptan, Furosemide
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 23, 2026, 1:07 AM EDT
Completed Phase 3 Interventional

Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management

NCT01584557
View directory record Official record
Conditions
Heart Failure
Interventions
Tolvaptan or Samsca, placebo or sugar pill
Drug
Lead sponsor
Cardiovascular Clinical Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
37
States / cities
Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 23, 2026, 1:07 AM EDT
Terminated Phase 4 Interventional Results available

Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia

NCT01890694
View directory record Official record
Conditions
Hyponatremia
Interventions
Tolvaptan, Placebo, Hepatic Encephalopathy Assessment, Quality of Life Assessment, Vital signs, Blood laboratory tests, Ascites Evaluation, Edema
Drug · Behavioral · Biological + 1 more
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 23, 2026, 1:07 AM EDT
Withdrawn Phase 4 Interventional

The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study

NCT01663662
View directory record Official record
Conditions
Heart Failure
Interventions
Tolvaptan, placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 23, 2026, 1:07 AM EDT
Completed Phase 4 Interventional

Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure

NCT01863511
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
loop diuretic, tolvaptan, ultrafiltration
Drug · Procedure
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Oct 23, 2026, 1:07 AM EDT
Completed Phase 2 Interventional

Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration

NCT05190744
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease, Nephrogenic Diabetes Insipidus, Acquired Nephrogenic Diabetes Insipidus, Congenital Nephrogenic Diabetes Insipidus
Interventions
PB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 23, 2026, 1:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study Comparing Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed Intact

NCT01261481
View directory record Official record
Conditions
Healthy
Interventions
Tolvaptan
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 40 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 7, 2012 · Synced Oct 23, 2026, 1:07 AM EDT
Completed Phase 3 Interventional Results available

Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure

NCT01644331
View directory record Official record
Conditions
Heart Failure, Dyspnea
Interventions
Tolvaptan, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
18
States / cities
Aurora, Colorado • Atlanta, Georgia • Gainesville, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 23, 2026, 1:07 AM EDT
Completed Phase 3 Interventional Results available

Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT00428948
View directory record Official record
Conditions
Polycystic Kidney Disease, Autosomal Dominant
Interventions
Tolvaptan, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
1,445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
30
States / cities
Mobile, Alabama • Riverside, California • Stanford, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 1:07 AM EDT
Completed Phase 3 Interventional

"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia

NCT00072683
View directory record Official record
Conditions
Hyponatremias, Water Intoxication, Inappropriate ADH Syndrome, Water-Electrolyte Imbalances
Interventions
tolvaptan, placebo matching tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
23
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 23, 2026, 1:07 AM EDT
Terminated No phase listed Observational

Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients

NCT02215148
View directory record Official record
Conditions
Brain Injury, Hyponatremia
Interventions
Tolvaptan
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
St Louis, Missouri • Chapel Hill, North Carolina • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Oct 23, 2026, 1:07 AM EDT
Completed Phase 4 Interventional Results available

Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders

NCT02476409
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
tolvaptan, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 23, 2026, 1:07 AM EDT
Completed Phase 3 Interventional Results available

Tolvaptan Extension Study in Participants With ADPKD

NCT01214421
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,083 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
38
States / cities
Mobile, Alabama • Peoria, Arizona • Tempe, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 23, 2026, 1:07 AM EDT
Recruiting Phase 3 Interventional

A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

NCT04782258
View directory record Official record
Conditions
Autosomal Recessive Polycystic Kidney (ARPKD)
Interventions
Tolvaptan Suspension, Tolvaptan Tablets
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
28 Days to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 23, 2026, 1:07 AM EDT
Completed Phase 2 Interventional

Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients

NCT00043758
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
35
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 1:07 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Tolvaptan in Healthy Adults

NCT01973140
View directory record Official record
Conditions
Healthy
Interventions
Tolvaptan, Hypertonic saline infusion
Drug
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 55 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 1:07 AM EDT
Completed Phase 4 Interventional Results available

Tolvaptan in Hyponatremic Cancer Patients

NCT01199198
View directory record Official record
Conditions
Advanced Cancers
Interventions
Tolvaptan, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 23, 2026, 1:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

V2 Receptor Effects on Fluid Regulation and Performance

NCT02084797
View directory record Official record
Conditions
Electrolyte Imbalance, Hyponatremia, Hypernatremia
Interventions
V2R (Vasopressin 2 receptor)
Drug
Lead sponsor
Oakland University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Michigan
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 23, 2026, 1:07 AM EDT
Completed Phase 3 Interventional

Effect of Tolvaptan on Cognitive Function in Cirrhosis

NCT01556646
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy, Hyponatremia
Interventions
Tolvaptan
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 7, 2014 · Synced Oct 23, 2026, 1:07 AM EDT